A5006443491- Head and Neck Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Liver Disease Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis B Virus Studies
- Lung Cancer Research Studies
- Head and Neck Surgical Oncology
- Nausea and vomiting management
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- MRI in cancer diagnosis
- Colorectal Cancer Treatments and Studies
- Hepatitis C virus research
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Anesthesia and Pain Management
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- Pancreatic and Hepatic Oncology Research
- Medical Imaging Techniques and Applications
- Bone and Joint Diseases
- Liver Disease and Transplantation
Prince of Wales Hospital
2016-2025
Chinese University of Hong Kong
2016-2025
China National Offshore Oil Corporation (China)
2024-2025
Guangdong Pharmaceutical University
2024
SWOG Cancer Research Network
2023
Princess Margaret Cancer Centre
2021
Tuen Mun Hospital
2018
Pamela Youde Nethersole Eastern Hospital
2018
State Key Laboratory of Oncology in South China
2017
Newcastle upon Tyne Hospitals NHS Foundation Trust
2014
Most patients with hepatocellular carcinoma (HCC) have associated chronic liver disease, the severity of which is currently assessed by Child-Pugh (C-P) grade. In this international collaboration, we identify objective measures function/dysfunction that independently influence survival in HCC and then combine these into a model could be compared conventional C-P grade.We developed simple to assess function, based on 1,313 all stages from Japan, involved only serum bilirubin albumin levels....
Purpose This randomized trial compared the rates of delayed xerostomia between two-dimensional radiation therapy (2DRT) and intensity-modulated (IMRT) in treatment early-stage nasopharyngeal carcinoma (NPC). Patients Methods Between November 2001 December 2003, 60 patients with T1-2bN0-1M0 NPC were randomly assigned to receive either IMRT or 2DRT. Primary end point was incidence observer-rated severe at 1 year after based on Radiotherapy Oncology Group /European Organisation for Research...
Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in cancer patients with chronic HBV (hepatitis surface antigen [HBsAg] positive) undergoing cytotoxic chemotherapy. In who have resolved (HBsAg negative and antibody to core [anti-HBc] +/- [anti-HBs] positive), such incidence has been much less common until recent use rituximab. this study on HBsAg-negative/anti-HBc-positive lymphoma patients, the objectives were determine reactivation rate treated...
Single-agent doxorubicin has been widely used to treat unresectable hepatocellular carcinoma (HCC), but the response rate is low (< 20%) and there no convincing evidence for improved survival. Cisplatin, interferon, doxorubicin, fluorouracil (PIAF) in combination, by contrast, shown promise a phase II study. We compared PIAF patients with HCC III trial.Patients histologically confirmed were randomly assigned receive either or every 3 weeks, up six cycles. The primary endpoint was overall...
To compare the toxicities, tumor control, survival, and quality of life nasopharyngeal cancer (NPC) patients treated with sequential neoadjuvant chemotherapy followed by concurrent cisplatin-radiotherapy (CRT) or CRT alone.Previously untreated stage III to IVB NPC were randomly assigned (1) docetaxel 75 mg/m(2) cisplatin every 3 weeks for two cycles, 40 mg/m(2)/wk radiotherapy, (2) alone. Planned accrual was 30 per arm detect 20% difference toxicities based on 95% CIs.From November 2002...
This phase III randomized study compared concurrent cisplatin–radiotherapy (CRT) versus radiotherapy (RT) alone in patients with locoregionally advanced nasopharyngeal carcinoma. A total of 350 were randomly assigned to receive external RT or concurrently cisplatin at a dosage 40 mg/m 2 weekly. The primary endpoint was overall survival, and the median follow-up 5.5 years. 5-year survival 58.6% (95% confidence interval [CI] = 50.9% 66.2%) for arm 70.3% CI 63.4% 77.3%) CRT arm. In Cox...
Hepatitis B virus (HBV) infection is an important etiology for hepatocellular carcinoma (HCC). We aim to develop a simple clinical score in predicting the risk of HCC among HBV carriers.We first evaluated 1,005 patients and found that following five factors independently predicted development: age, albumin, bilirubin, DNA, cirrhosis. These variables were used construct prediction ranging from 0 44.5. The was validated another prospective cohort 424 patients.During median follow-up 10 years,...
PURPOSE: Nasopharyngeal carcinoma (NPC) is highly sensitive to both radiotherapy (RT) and chemotherapy. This randomized phase III trial compared concurrent cisplatin-RT (CRT) with RT alone in patients locoregionally advanced NPC. PATIENTS AND METHODS: Patients Ho’s N2 or N3 stage N1 nodal size ≥ 4 cm were receive cisplatin 40 mg/m 2 weekly up 8 weeks concurrently radical alone. The primary end point was progression-free survival (PFS). RESULTS: Three hundred fifty eligible randomized....
Purpose To evaluate the effect of combining circulating Epstein-Barr viral (EBV) DNA load data with TNM staging in pretherapy prognostication nasopharyngeal carcinoma (NPC). Patients and Methods Three hundred seventy-six patients all stages NPC were studied. Pretreatment plasma/serum EBV concentrations quantified by a polymerase chain reaction assay. Determinants overall survival assessed multivariate analysis. Survival probabilities patient groups, segregated clinical stage (I, II, III, or...
We aimed to investigate the impact of hepatitis B virus (HBV) DNA and HBV genotypes/subgenotypes on risk hepatocellular carcinoma (HCC).A prospective cohort patients infected with chronic in a surveillance program for HCC since 1997 was studied. Ultrasound alpha-fetoprotein evaluation were regularly performed detect HCC. Risk factors relationship between genotypes determined.Among 1,006 median follow-up 7.7 years, 86 (8.5%) developed With reference low stratum (log </= 4.5 copies/mL), hazard...
Purpose The contribution of adjuvant chemotherapy after chemoradiation therapy (CRT) in nasopharyngeal cancer (NPC) remains controversial. Plasma Epstein-Barr virus (EBV) DNA is a potential biomarker subclinical residual disease NPC. In this prospective, multicenter, randomized controlled trial, we used plasma EBV to identify patients with NPC at higher risk relapse for chemotherapy. Patients and Methods Eligible histologically confirmed Union International Cancer Control stage IIB IVB,...
There are limitations in using radiologic evaluation to assess the treatment outcome of patients with hepatocellular carcinoma (HCC). The use serial alpha-fetoprotein (AFP) monitoring response has not been rigorously evaluated. We aimed study clinical value AFP trend an attempt validate as a surrogate serologic end point.Participants from phase III randomized trial systemic chemotherapy HCC were studied. Serum was prospectively collected parallel and outcome. defined decrease more than 20%...
Purpose To determine the diagnostic performance of diffusion-weighted (DW) imaging for prediction treatment failure in primary head and neck squamous cell carcinoma (HNSCC). Materials Methods The study was approved by local institutional ethics committee conducted with informed written consent patients HNSCC treated radiation therapy chemotherapy. DW tumor performed before 37 repeated within 2 weeks 30 patients. Histograms apparent diffusion coefficients (ADCs) were analyzed, mean ADC,...
Epigenetic aberrations have been reported in hepatocellular carcinoma (HCC). In this study of patients with unresectable HCC and chronic liver disease, epigenetic therapy the histone deacetylase inhibitor belinostat was assessed. The objectives were to determine dose-limiting toxicity maximum-tolerated dose (MTD), assess pharmacokinetics phase I, activity explore potential biomarkers for response II.
Genomic gain represents an important mechanism in the activation of proto-oncogenes. In many instances, induced oncogenes hold clinical implications both as prognostic markers and targets for therapeutic design. hepatocellular carcinoma (HCC), although chromosomal gains are common, information on underlying remains minimal. Here, we examined 7 causal sites HCC overexpressed genes by array-based transcriptional mapping. 22 cell lines early passages cultures studied, clusters up-regulated were...
Application of curative therapy for hepatocellular carcinoma is crucially dependent on underlying liver function. Using the recently described ALBI grade we examined long-term impact dysfunction survival early-stage (HCC) patients. This cohort study comprised 2559 HCC patients from different geographic regions, all treated with intent. We also relation between indocyanine green (ICG) clearance and score. Survival was measured date treatment to death or last follow-up. The score correlated...
The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC. Data on the mTOR inhibitor, temsirolimus, limited HCC patients with concomitant chronic liver disease. objectives of this study were: (1) In phase I, to determine DLTs and MTD temsirolimus disease; (2) II, assess activity HCC, (3) explore potential biomarkers for response.Major eligibility criteria included histologically confirmed advanced adequate organ function. Phase I part study, was given weekly 3-weekly cycle; dose...
The albumin-bilirubin (ALBI) grade is a recently reported, simpler, more objective, and evidence-based alternative to the Child-Pugh (CP) score for hepatocellular carcinoma (HCC). We aimed study whether ALBI could substitute CP in Barcelona Clinic Liver Cancer (BCLC) HCC.An international multicentre cohort (n = 3696) was accrued compare prognostic performance of CP-based ALBI-based BCLC system, terms homogeneity, discriminatory ability, monotonicity gradients that were numerically reflected...